John Lim Confirmed for Third Consecutive Term as CEO of Samsung Biologics
John Lim's third consecutive term as CEO of Samsung Biologics has been virtually confirmed.
According to the bio industry on December 30, Samsung Biologics recently decided to reappoint John Lim as CEO at a board meeting. The reappointment is expected to be finalized at the regular general shareholders' meeting in March next year.
Having taken office in December 2020, John Lim will now begin his third term.
During his tenure, Samsung Biologics has been recognized for remarkable growth both quantitatively and qualitatively. In 2022, the company became the first Korean bio company to surpass 3 trillion won in sales, and last year, it exceeded 4 trillion won.
The market attributes this achievement to the company's rapid adaptation to a rapidly changing environment, marked by the significant expansion of global big pharma clients and increased production capacity.
Recently, Samsung Biologics acquired a production facility in Rockville, Maryland, USA, for $280 million (approximately 413.6 billion won).
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
With this acquisition, Samsung Biologics now boasts the world's largest production capacity, totaling 845,000 liters. The company plans to complete its second bio campus by 2032, aiming to secure a "super-gap" production capacity of 1,385,000 liters.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.